Ukusasaza i-B-cell lymphoma enkulu (i-DLBCL), i-NOS, i-GCB subtype, i-primary central nervous system lymphoma-01

NgoDisemba ka-2019, uMnu. Wang, utitshala osuka kuMntla-mpuma weTshayina, waqala ukuqaqanjelwa yintloko. Ngomhla we-19 kaDisemba, ngo-2019, iimvavanyo zokuxilonga zibonise oku kulandelayo: I-PET-CT ibonise isithunzi soxinaniso esonyuswe kakhulu kwi-FDG metabolism kwindawo yasekhohlo yangaphambili kunye ne-corpus callosum knee area (malunga ne-3.4 * 1.9 cm, SUVmax = 34.4). I-Biopsy kunye ne-immunohistochemistry iqinisekisile ukusabalalisa i-B-cell lymphoma enkulu (i-DLBCL, i-NOS, i-GCB subtype), kunye ne-immunophenotype ebonisa i-Ki67 (50% +), i-CD19 (+), i-CD20 (+), i-PAX5 (+), i-CD79 (+), MUM1(+), BCL(+), CD10(-/+), CD2(minor+). Uhlalutyo lwe-Cerebrospinal fluid lubonise i-6% yeeseli ze-lymphoid ezingavuthiweyo ezinokuguquguquka kwe-morphological. Ukuxilongwa kwakuyi-primary central nervous system lymphoma (DBCL, GCB subtype).

Emva kokuphanda iinketho zonyango kwi-intanethi, uMnu. Wang wafunda malunga neSibhedlele saseLu Dao Pei sonyango lwe-immunotherapy kwaye wafuna ngokukhawuleza ubuchule babo. Ukulandela uhlolo olucokisekileyo lomzimba kunye nohlalutyo olucokisekileyo lweqela leengcaphephe zesibhedlele, kwagqitywa ekubeni uMnu. Wang athathe inxaxheba kulingo lwezonyango lwe-CART, kusetyenziswa iiseli ze-CD19 CART. Ufumene i-autologous CD19 CAR-T cell infusion ngoAprili 24, 2023. NgoJulayi 30, 2023, wavavanywa ukuba ufumene uxolelo olupheleleyo (CR) kwaye sele ebuyele kubomi obuqhelekileyo.